跳到正文
原文
Medical Xpress·· 3 天前AI 评分45

新 SARS-CoV-2 变异株 PJ.2.1:疫苗抗体提供保护

New SARS-CoV-2 variant PJ.2.1: Vaccine antibodies provide protection

AI 导读

研究发现,新 SARS-CoV-2 变异株 PJ.2.1 能更有效地与 ACE2 受体结合并侵入某些细胞,但接种当前针对 XFG 变异株的加强疫苗仍能有效中和该变异株。研究团队建议,如果变异株获得逃逸抗体反应的突变,疫苗保护效果可能减弱。

正文
New SARS-CoV-2 Variant PJ.2.1: Vaccine Antibodies Provide Protection
Credit: AI-generated (ChatGPT)/The German Primate Center

Germany's COVID-19 traffic light is red, and the number of infections is high. But how well is the population protected against the virus variants currently circulating? The new SARS-CoV-2 variant PJ.2.1 has been spreading since May and has long since reached Europe. It traces back to an older viral lineage that has since largely disappeared from the infection landscape. However, the virus likely persisted in a person with a long-term infection and underwent significant changes through numerous mutations.

Researchers from the Infection Biology Unit at the German Primate Center—Leibniz Institute for Primate Research, in collaboration with colleagues from Hannover Medical School, investigated how efficiently PJ.2.1 can penetrate human cells and how well antibodies from vaccinated individuals neutralize the new variant.

The results show that PJ.2.1 binds more strongly than the other virus variants studied to the ACE2 receptor, which serves as the entry point for SARS-CoV-2 into human cells, and enters certain cells that produce only small amounts of ACE2 more effectively.

Despite these changes, the new variant was effectively neutralized by antibodies produced following vaccination with the current booster vaccine, which has been adapted to the XFG variant. The results suggest that vaccination provides protection against PJ.2.1. However, this could change if the variant acquires additional mutations that enable it to evade the immune response.

The findings have been published in the Journal of Infection and The Lancet Infectious Diseases.

A hallmark of SARS-CoV-2 is the continuous emergence of new viral variants with changes in the spike protein, which allow the virus to partially evade the antibody response. Often, such variants differ from their predecessors by only a few mutations in the spike protein.

These can alter binding sites for antibodies and/or influence binding to the ACE2 receptor, which the virus uses to enter human cells. In addition, however, variants may also emerge that are characterized by an unusually large number of mutations—particularly in the spike protein—and thus evade the existing antibody response particularly efficiently.

Such so-called saltation variants can develop during long-term infections. In this process, the virus has the opportunity over an extended period to replicate within the body of an infected person and gradually undergo significant changes.

Since May 2026, a new saltation variant of SARS-CoV-2 has been spreading: PJ.2.1. The variant was first detected in Canada and subsequently spread to the United States. Until now, it was unclear how efficiently PJ.2.1 can penetrate cells and how susceptible the variant is to neutralizing antibodies. In particular, it was not known how effectively antibodies produced following vaccination can inhibit PJ.2.1.

A research team led by infection biologists Markus Hoffmann and Stefan Pöhlmann from the German Primate Center—Leibniz Institute for Primate Research, in collaboration with Georg Behrens' research group at Hannover Medical School, investigated these questions.

Their findings show that PJ.2.1 is spreading rapidly in Canada, the U.S. and Spain; its prevalence is also rising in the Netherlands and France. Spread in Germany is therefore to be expected. With infection rates remaining high overall, the variant has been detected in all age groups. There is currently no evidence of more severe disease progression or new symptoms compared to other SARS-CoV-2 variants.

The researchers found that the spike protein of PJ.2.1 binds more strongly to ACE2. Consistent with this, PJ.2.1 was better able than other variants to penetrate cells that produce only small amounts of the ACE2 receptor. PJ.2.1 was effectively inhibited by antibodies from individuals who had been vaccinated with the XFG-adapted mRNA vaccine Comirnaty, which is currently in use in Germany.

In contrast, the SARS-CoV-2 variant BA.3.2, which is primarily detected in children, was only inadequately inhibited by these antibodies.

"Our results suggest that PJ.2.1 is likely spreading worldwide due to improved ACE2 binding," says Hoffmann. "We assume that the XFG-adapted vaccine provides effective protection against PJ.2.1 as well as against the XFG viruses that are also circulating—at least as long as these viruses do not acquire mutations that allow them to evade the antibody response more effectively."

Pöhlmann adds, "Notably, neither the vaccine used last season nor the currently available vaccine elicits an antibody response that efficiently blocks BA.3.2 from entering cells. Since BA.3.2 is detected primarily in children, it should be investigated whether an additional component tailored to this variant could be included in future COVID-19 vaccines."

Publication details

Markus Hoffmann et al., Epidemiology and virological characteristics of the emerging SARS-CoV-2 variant PJ.2.1, Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106886

Christine Happle et al., Humoral immunity after mRNA SARS-CoV-2 XFG vaccination, The Lancet Infectious Diseases (2026). DOI: 10.1016/s1473-3099(26)00569-4

Journal information: Lancet Infectious Diseases

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: New SARS-CoV-2 variant PJ.2.1: Vaccine antibodies provide protection (2026, November 17) retrieved 17 November 2026 from https://medicalxpress.com/news/2026-11-sars-cov-variant-pj21-vaccine.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com